Greenwich LifeSciences (GLSI) Financial Statements
Greenwich LifeSciences Financial Overview
Greenwich LifeSciences's market cap is currently $255.55M. The company's EPS TTM is $-1.54; its P/E ratio is -11.30; Greenwich LifeSciences is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -1.78K | $ -3.61K | $ -3.61K | $ -3.61K | $ -3.61K |
| Operating Income | $ -19.45M | $ -17.64M | $ -9.33M | $ -8.04M | $ -4.60M |
| EBITDA | $ -19.36M | $ -17.41M | $ -8.89M | $ -7.82M | $ -4.57M |
| Net Income | $ -19.36M | $ -17.41M | $ -8.89M | $ -7.83M | $ -4.57M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 6.18M | $ 4.09M | $ 6.99M | $ 13.47M | $ 27.20M |
| Total Assets | $ 6.18M | $ 4.09M | $ 6.99M | $ 13.48M | $ 27.22M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -6.18M | $ -4.09M | $ -6.99M | $ -13.47M | $ -27.20M |
| Total Liabilities | $ 5.82M | $ 3.19M | $ 294.41K | $ 262.90K | $ 385.17K |
| Stockholders' Equity | $ 353.22K | $ 908.63K | $ 6.70M | $ 13.21M | $ 26.83M |
| Cash Flow | |||||
| Free Cash Flow | $ -9.91M | $ -7.27M | $ -6.48M | $ -6.20M | $ -4.29M |
| Operating Cash Flow | $ -9.91M | $ -7.27M | $ -6.48M | $ -6.20M | $ -4.29M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 12.00M | $ 4.37M | $ 0.00 | $ -7.54M | $ 2.84M |
Currency in USD